1. Up Front

   Up Front 24 August 2023 Pages: 1757 - 1758

   

2. Daniel Porte Jr, 13 August 1931–13 May 2023

   • Steven E. Kahn
   • Michael W. Schwartz

   IN MEMORIAM 04 August 2023 Pages: 1759 - 1761

   

3. Incretins: turning the venom into the antidote

   • Anna Krook
   • Hindrik Mulder

   Editorial 18 August 2023 Pages: 1762 - 1764

4. The expanding incretin universe: from basic biology to clinical translation

   • Daniel J. Drucker
   • Jens J. Holst

   Review 28 March 2023 Pages: 1765 - 1779

   

5. Incretin hormones and type 2 diabetes

   • Michael A. Nauck
   • Timo D. Müller

   Review Open access 11 July 2023 Pages: 1780 - 1795

   

6. Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy

   • Matthias Tschöp
   • Ruben Nogueiras
   • Bo Ahrén

   Review Open access 20 May 2023 Pages: 1796 - 1808

   

7. Incretins beyond type 2 diabetes

   • Chantal Mathieu
   • Iraj Ahmadzai

   Review 08 August 2023 Pages: 1809 - 1819

   

8. Incretins and cardiovascular disease: to the heart of type 2 diabetes?

   • Anna Solini
   • Domenico Tricò
   • Stefano Del Prato

   Review Open access 05 August 2023 Pages: 1820 - 1831

   

9. Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy

   • Jonathan Goldney
   • Jack A. Sargeant
   • Melanie J. Davies

   Review Open access 19 August 2023 Pages: 1832 - 1845

   

10. The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease

    • Christine R. Andreasen
    • Andreas Andersen
    • Tina Vilsbøll

    Invited Review 27 July 2023 Pages: 1846 - 1858

    

11. Socioeconomic aspects of incretin-based therapy

    • Thomas Karagiannis
    • Eleni Bekiari
    • Apostolos Tsapas

    Review Open access 12 July 2023 Pages: 1859 - 1868

    

12. SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study

    • Matthew Anson
    • Sizheng S. Zhao
    • Uazman Alam

    Article Open access 28 July 2023 Pages: 1869 - 1881

    

13. Metformin for the prevention of diabetes among people with HIV and either impaired fasting glucose or impaired glucose tolerance (prediabetes) in Tanzania: a Phase II randomised placebo-controlled trial

    • Anupam Garrib
    • Sokoine Kivuyo
    • on behalf of the META trial team

    Article Open access 18 July 2023 Pages: 1882 - 1896

    

14. Strength training is more effective than aerobic exercise for improving glycaemic control and body composition in people with normal-weight type 2 diabetes: a randomised controlled trial

    • Yukari Kobayashi
    • Jin Long
    • Latha Palaniappan

    Article 26 July 2023 Pages: 1897 - 1907

    

15. Glycaemic control, risk of hypoglycaemia and all-cause mortality in new users of second-generation basal insulin with type 2 diabetes and chronic kidney disease: a nationwide register-based cohort study

    • Vanja Kosjerina
    • Bendix Carstensen
    • Dorte Vistisen

    Short Communication 28 July 2023 Pages: 1908 - 1913

    

16. Genetic associations vary across the spectrum of fasting serum insulin: results from the European IDEFICS/I.Family children’s cohort

    • Kirsten Mehlig
    • Ronja Foraita
    • on behalf of the I.Family consortium

    Article Open access 07 July 2023 Pages: 1914 - 1924

    

17. Hyperglucagonaemia in diabetes: altered amino acid metabolism triggers mTORC1 activation, which drives glucagon production

    • Yael Riahi
    • Aviram Kogot-Levin
    • Gil Leibowitz

    Extended Article 22 July 2023 Pages: 1925 - 1942

    

18. Reversal of dual epigenetic repression of non-canonical Wnt-5a normalises diabetic corneal epithelial wound healing and stem cells

    • Ruchi Shah
    • Tanya M. Spektor
    • Alexander V. Ljubimov

    Article Open access 18 July 2023 Pages: 1943 - 1958